Table 2.
Compound | Vehicle | 1 nM Estradiol |
---|---|---|
1a | 0 | 0 |
1b | --- | --- |
1c | ++ | 0 |
1d | --- | --- |
1e | ++ | 0 |
1f | +++a | 0a |
1g | 0 | 0 |
1h | +++ | 0 |
1i | +++ | 0 |
1j | --- | --- |
1k | + | 0 |
1l | +++a | 0a |
1m | + | 0 |
2a | +++ | 0 |
2b | 0 | 0 |
2c | + | 0 |
2d | + | 0 |
2e | +a | 0a |
2f | 0 | 0 |
2g | 0 | 0 |
2h | +++ | 0 |
2i | 0 | 0 |
2j | 0 | 0 |
2k | ++ | 0 |
2l | +++ | 0 |
2m | + | 0 |
(+) Denotes a greater than 50% increase in reporter gene activity at compound concentration <20 μM.
(++) Denotes a greater than 50% increase in reporter gene activity at compound concentration between 20–50 μM.
(+++) Denotes a greater than 50% increase in reporter gene activity at compound concentration >50 μM.
(-) Denotes a greater than 50% decrease in reporter gene activity at compound concentration >50 μM.
(--) Denotes a greater than 50% decrease in reporter gene activity at compound concentration <between 20–50 μM.
(---) Denotes a greater than 50% decrease in reporter gene activity at compound concentration <20 μM.
(0) Denotes a less than 20% change in reporter gene activity. 4 Hydroxytamoxifen was used as an antagonist control.
Denotes cell death at concentration greater than 50 μM.
Denotes precipitation of compound from solution.